CHEK2 and prostate neoplasm: The CHEK2 p.R180C variant was also previously reported in 2.1% (2/94) prostate tumor samples of Caucasian American patients who were diagnosed before the age of 59 and in germline DNA of 1/423 (0.24%) unaffected men [31].